The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis

BackgroundThe aim of this study was to evaluate the association between miR-34 family expression and overall survival (OS) and progression-free survival (PFS) in women with ovarian cancer.MethodsLiterature searches were conducted using databases such as PubMed, Cochrane Library, EMBASE, Web of Scien...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiulan Luo, Xiaolu Li, Chaolin Chen, Jing Yang, Hong Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1499163/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850038523922481152
author Xiulan Luo
Xiaolu Li
Chaolin Chen
Jing Yang
Hong Zheng
author_facet Xiulan Luo
Xiaolu Li
Chaolin Chen
Jing Yang
Hong Zheng
author_sort Xiulan Luo
collection DOAJ
description BackgroundThe aim of this study was to evaluate the association between miR-34 family expression and overall survival (OS) and progression-free survival (PFS) in women with ovarian cancer.MethodsLiterature searches were conducted using databases such as PubMed, Cochrane Library, EMBASE, Web of Science, Wanfang, and CNKI to identify studies reporting pooled hazard ratios (HRs) and 95% confidence intervals (CIs) examining the relationship between miR-34 family expression and overall survival (OS) or progression-free survival (PFS) in female patients with ovarian cancer. All potentially relevant studies were assessed and then pooled.ResultsThere were a total of seven literatures included in this systematic review and meta-analysis, which included 672 women. There was a significant improvement in survival for women with ovarian cancer when miR-34s expression was higher (OS, HR = 0.70, 95% CI:0.57–0.86; PFS, HR = 0.48, 95% CI:0.31–0.75). A subgroup analysis of miR-34 family members showed that differences between groups greatly affected PFS (HR = 0.50, 95% CI: 0.40–0.63).ConclusionBased on the results of this review, it appears that ovarian cancer women with high expression of miR-34s may have a better chance of surviving.Systematic Review Registration: PROSPERO (CRD42024499203).Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024499203.
format Article
id doaj-art-6c59cb134e9549209fa69bdaf129ef3b
institution DOAJ
issn 2234-943X
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-6c59cb134e9549209fa69bdaf129ef3b2025-08-20T02:56:33ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011510.3389/fonc.2025.14991631499163The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysisXiulan LuoXiaolu LiChaolin ChenJing YangHong ZhengBackgroundThe aim of this study was to evaluate the association between miR-34 family expression and overall survival (OS) and progression-free survival (PFS) in women with ovarian cancer.MethodsLiterature searches were conducted using databases such as PubMed, Cochrane Library, EMBASE, Web of Science, Wanfang, and CNKI to identify studies reporting pooled hazard ratios (HRs) and 95% confidence intervals (CIs) examining the relationship between miR-34 family expression and overall survival (OS) or progression-free survival (PFS) in female patients with ovarian cancer. All potentially relevant studies were assessed and then pooled.ResultsThere were a total of seven literatures included in this systematic review and meta-analysis, which included 672 women. There was a significant improvement in survival for women with ovarian cancer when miR-34s expression was higher (OS, HR = 0.70, 95% CI:0.57–0.86; PFS, HR = 0.48, 95% CI:0.31–0.75). A subgroup analysis of miR-34 family members showed that differences between groups greatly affected PFS (HR = 0.50, 95% CI: 0.40–0.63).ConclusionBased on the results of this review, it appears that ovarian cancer women with high expression of miR-34s may have a better chance of surviving.Systematic Review Registration: PROSPERO (CRD42024499203).Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024499203.https://www.frontiersin.org/articles/10.3389/fonc.2025.1499163/fullmeta-analysismicroRNAmiR-34sovarian cancerprognosis
spellingShingle Xiulan Luo
Xiaolu Li
Chaolin Chen
Jing Yang
Hong Zheng
The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis
Frontiers in Oncology
meta-analysis
microRNA
miR-34s
ovarian cancer
prognosis
title The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis
title_full The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis
title_fullStr The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis
title_full_unstemmed The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis
title_short The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis
title_sort prognostic value of mir 34 family in ovarian cancer a systematic review and meta analysis
topic meta-analysis
microRNA
miR-34s
ovarian cancer
prognosis
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1499163/full
work_keys_str_mv AT xiulanluo theprognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT xiaoluli theprognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT chaolinchen theprognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT jingyang theprognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT hongzheng theprognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT xiulanluo prognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT xiaoluli prognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT chaolinchen prognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT jingyang prognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis
AT hongzheng prognosticvalueofmir34familyinovariancancerasystematicreviewandmetaanalysis